Terms ending in 2031
Every in-force patent on CureVac AG's record whose computed term ends in 2031, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 8,968,746 | Complexation of Nucleic Acids with Disulfide-Crosslinked Cationic Components for Transfection and Immunostimulation In force · High confidence | Curevac SE | In force | High confidence | |
| US 9,234,013 | Nucleic Acid Comprising or Coding for a Histone Stem-Loop and a Poly(A) Sequence or a Polyadenylation Signal for Increasing the Expression of an Encoded Protein In force · High confidence | Curevac SE | In force | High confidence | |
| US 9,839,697 | Nucleic Acid Comprising or Coding for a Histone Stem-Loop and a Poly(A) Sequence or a Polyadenylation Signal for Increasing the Expression of an Encoded Protein In force · Medium confidence | Curevac SE | In force | Medium confidence | |
| US 10,010,592 | Nucleic Acid Comprising or Coding for a Histone Stem-Loop and a Poly(A) Sequence or a Polyadenylation Signal for Increasing the Expression of an Encoded Tumour Antigen In force · Medium confidence | Curevac SE | In force | Medium confidence | |
| US 10,232,024 | Nucleic Acid Comprising or Coding for a Histone Stem-Loop and a Poly(A) Sequence or a Polyadenylation Signal for Increasing the Expression of an Encoded Allergenic Antigen or an Autoimmune Self-Antigen In force · Medium confidence | Curevac SE | In force | Medium confidence | |
| US 10,653,799 | Nucleic Acid Comprising or Coding for a Histone Stem-Loop and a Poly(A) Sequence or a Polyadenylation Signal for Increasing the Expression of an Encoded Protein In force · Medium confidence | Curevac SE | In force | Medium confidence | |
| US 11,110,156 | Nucleic Acid Comprising or Coding for a Histone Stem-Loop and a Poly(A) Sequence or a Polyadenylation Signal for Increasing the Expression of an Encoded Tumour Antigen In force · High confidence | Curevac SE | In force | High confidence | |
| US 12,109,275 | Nucleic Acid Comprising or Coding for a Histone Stem-Loop and a Poly(A) Sequence or a Polyadenylation Signal for Increasing the Expression of an Encoded Protein In force · Medium confidence | Curevac SE | In force | Medium confidence | |
| US 9,226,959 | Nucleic Acids Comprising formula (NuGlXmGnNv)a and Derivatives Thereof as Immunostimulating Agent/Adjuvant In force · High confidence | Curevac SE | In force | High confidence |
9 of 9 patents shown. Soonest term end first, then patent number.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.